# What is driving the comeback story in biopharma?

Page: https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma
Text version: https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma.md
Podcast: [UBS Global Research Pod Hub](https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142)
Published: 2026-02-13T15:09:22+00:00
Episode link: https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3
Audio file: https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ubs-global-research-pod-hub-6511142/episodes/what-is-driving-the-comeback-story-in-biopharma
Duration seconds: 911

## Resource

With drug pricing cuts easing, investor interest is returning, driven by fresh innovation, active M&A, and rotation into a long undervalued sector. Dimiter Tassev, UBS Healthcare Advisory Sales Specialist, speaks with Michael Yee, Global Head of Biotechnology Research at UBS investment Bank, about the outlook for US biopharma. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ubs-global-research-pod-hub-6511142/episodes/what-is-driving-the-comeback-story-in-biopharma/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.